Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft

(2015) Alexandra Borodovsky et al.   Oncotarget

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

(2015) Sevin Turcan et al.   Oncotarget

Update on the pharmacotherapy for myelodysplastic syndromes

(2014) Vu H Duong et al.   EXPERT OPINION ON PHARMACOTHERAPY

Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults

(2014) Heidi D. Klepin et al.   JOURNAL OF CLINICAL ONCOLOGY

The state of the union on treatment of acute myeloid leukemia

(2014) Ashkan Emadi et al.   LEUKEMIA & LYMPHOMA

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis

(2014) Jie Jin et al.   PLoS One

Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)

(2013) Bernard Tawfik et al.   ANNALS OF HEMATOLOGY

Targeting IDH: the next big thing in AML

(2013) M. Levis   BLOOD

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

(2013) A. Chaturvedi et al.   BLOOD

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations

(2013) Ashkan Emadi et al.   EXPERIMENTAL HEMATOLOGY

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

(2013) Bhavana Bhatnagar et al.   LEUKEMIA & LYMPHOMA

Lack of association ofIDH1, IDH2andDNMT3Amutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents

(2013) Courtney D. DiNardo et al.   LEUKEMIA & LYMPHOMA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response

(2012) A. T. Fathi et al.   BLOOD

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients

(2011) M M Patnaik et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

(2010) S. Abbas et al.   BLOOD

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication

(2010) Peter Paschka et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD